Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation

Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation

Background: The kallikrein kinin system (KKS) is an established pharmacological target for the treatment and prevention of attacks in hereditary angioedema (HAE). Proteolytic activities of FXIIa and single-chain Factor XII (FXII) zymogen contribute to KKS activation and thereby may play roles in bot...

Full description

Bibliographic Details
Main Authors: Allen C. Clermont, Nivetha Murugesan, Hannah J. Edwards, Daniel K. Lee, Natasha P. Bayliss, Edward J. Duckworth, Stephen J. Pethen, Sally L. Hampton, David Gailani, Edward P. Feener
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Pharmacology
Subjects:
factor XIIa inhibitor
FXII zymogen
hereditary angioedema
kallikrein-kinin system
HAE
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1287487/full

Similar Items

Similar Items